SUMMARY. In a retrospective study, the results after resection of carcinoma of the gastric cardia in the era without neoadjuvant therapy or extended lymph node dissection were evaluated. All 184 patients who underwent resection between January 1983 and December 1993 were included. Recurrence of disease, survival and prognostic factors were determined. The overall cumulative 5-year recurrence rate was 71% and the survival rate 23%. Multivariate analysis identi®ed locoregional lymph node and distant metastases as the crucial prognosticators of recurrence of disease and survival. These results were similar to those from a previous study concerning our patients operated during the years 1983±88. The prognosis of a resected cardiacarcinoma has remained unchanged in our hands over the past 10 years. These results stress the importance of exploring new ways, such as the use of new diagnostic tools, to optimize preoperative patient selection and more aggressive treatment regimens to improve ®nal outcome.
INTRODUCTION
Treatment of adenocarcinoma of the gastric cardia carries poor survival rates. Metastatic disease is present in many patients at the time of diagnosis of the disease. Nevertheless, even when the patient cannot be cured, resection is often considered the most eective means of palliation.
Previously, we reported in a smaller series on the outcome after resection of carcinoma of the gastric cardia. 1 We decided to evaluate the data of all patients that had been operated on for this disease in the decade before the introduction of novel treatment options such as neoadjuvant therapy and extended lymph node dissection to detect any improvements in outcome compared with the previous report. If present, such improvements should mainly be attributed to advances in perioperative care. If not, this would be a strong argument in favor of exploring new ways of patient selection and treatment, using new diagnostic and therapeutic options.
Also, in the present study, an analysis was performed to identify independent factors in¯uencing outcome after surgery. Such factors should be looked for in the preoperative work-up in an attempt to tailor the treatment to the patient.
PATIENTS AND METHODS
A tumor was de®ned as an adenocarcinoma of the gastric cardia when it was con®ned to the cardia, when it was located in the fundus of the stomach and had reached the cardia, or when such tumor had crossed over to the distal esophagus. By de®nition, carcinoma arising in Barrett's esophagus was not included. 2 By some, the last carcinoma is considered clinically and epidemiologically a separate entity. 3 Between 1 January 1983 and 31 December 1993, 184 patients underwent resection of their cardia carcinoma at the Department of General Surgery, Erasmus University Hospital, Rotterdam, The Netherlands. For this study, the information of the database of the Rotterdam Esophageal Tumor Study Group was used. In the same period, in 38 additional cases, resection was not performed because of the presence of metastatic lymph nodes at the celiac axis (22 cases), peritoneal metastases (14 patients), or liver metastases (two cases). These patients were excluded from the study.
In 177 patients, partial or subtotal esophagectomy was performed: in 133 with removal of the cardia and in 44 with removal of the entire stomach. In seven cases, resection was limited to a total gastrectomy. Before 1987, esophagectomy was performed by laparotomy and separate thoracotomy with an intrathoracic anastomosis. Thereafter, the transhiatal approach with blunt dissection of the upper twothirds of the esophagus and a cervical esophagogastrostomy with creation of a stomach tube has been preferred. 4 Perigastric lymph nodes and those around the distal esophagus and celiac axis were removed. No extended lymph node dissection was performed.
Some of our patients received radiotherapy. Before 1987, preoperative radiation therapy was given in our institution by protocol to patients with tumor invasion of the esophagus. This included 43 patients of the present series. This policy was based on studies in which a combined modality treatment strategy of preoperative radiation therapy and surgery was used for patients with esophageal cancer, suggesting superiority to surgery alone. 5, 6 Until 1987, post-operative radiation therapy was administered to patients with a T3 or T4 tumor status and patients with positive lymph nodes or residual tumor at the resection margins. Later prospective studies showed no bene®cial eects of pre-or post-operative radiation therapy on recurrence of disease or on survival after resection of a carcinoma of the esophagus or the cardia.
7±9 Therefore, after 1986, only selected patients in whom a macroscopically irradical resection was performed underwent post-operative radiation.
Post-operative histologic tumor classi®cation was performed according to the TNM criteria for carcinoma of the stomach as established by the International Union Against Cancer/American Joint Committee on Cancer 10 (Tables 1 and 2 ). In this system, positive lymph nodes around the stomach or the distal intra-abdominal esophagus and within 3 cm of the tumor are classi®ed as N1 nodes. N2 lymph nodes are situated perigastric, but more than 3 cm from the tumor, or around the celiac trunk, left gastric artery, splenic artery or common hepatic artery. Para-aortic and paraesophageal lymph nodes and those along the proper hepatic artery or in the splenic hilus are considered to be distant metastases.
Both locoregional recurrences and distant metastases were considered manifestations of recurrent disease. Survival rates and rates of recurrence were calculated on an actuarial basis with the Kaplan± Meier method. Comparison between these curves was made with the use of the log-rank test. Multivariate Cox regression analysis was carried out to identify independent prognostic factors. Intercurrent deathcorrected survival was calculated by considering the patients who died of causes unrelated to their carcinoma as having been withdrawn from the study at the date of death; p 0.05 (two-sided) was considered the limit of signi®cance. Patient follow-up was complete.
RESULTS
Of the 184 patients in this study, 157 were men and 27 women, with a mean age at operation of 62 years (range 35±85). Average length of follow-up was 26 months.
The distribution according to the subclasses of the postoperative TNM staging system is given in Table 2 . IA  T1N0M0  IB  T1N1M0, T2N0M0  II  T1N2M0, T2N1M0, T3N0M0  IIIA  T2N2M0, T3N1M0, T4N0M0  IIIB  T3N2M0, T4N1M0  IV T4N2M0, TxNxM1 
Recurrence
Recurrence of disease was found in 102 patients. All recurrences appeared within 4.5 years after operation. No dierence in recurrence rate was observed between the dierent levels of tumor penetration (T-stage, Table 2 ). The recurrence rate was signi®cantly higher in the presence of positive locoregional lymph nodes than when these were absent (p < 0.001, Fig. 1A ). No dierence was observed between positive nodes at the N1 or N2 location. None of the patients with metastases remained free of disease compared with 32% of those without (p < 0.001, Fig. 1B ). With decreasing grade of radicality of resection, with decreasing grade of dierentiation of the tumor or with increasing TNM stage, a trend towards a higher recurrence rate was observed.
Survival
The in-hospital mortality rate was 4.3% (eight patients). Of our study group, 121 patients died during follow-up, of whom only 14 without evidence of recurrent disease. The overall 5-year survival rate was 23%. This diered only slightly from the intercurrent death-corrected rate of 27%, indicating that only few patients died without prior recurrence of disease. Five-year survival in relation to the TNM classi®cation was as follows (Table 2) : no dierence was observed between the dierent T-stages; 38% of the patients without involvement of the lymph nodes survived 5 years compared with 15% with positive nodes (N1 or N2) (p < 0.001, Fig. 2A) ; 25% of the patients without metastases were alive after 5 years, but none of those in whom metastases were present (p < 0.001, Fig. 2B ). The median survival for patients with N0 nodal status was 30 months compared with 12 months for those with N1 or N2 status; these ®gures were 18 and 9 months in cases of a M0 and M1 classi®cation respectively.
As with recurrence of disease, there was a trend towards increasing survival with increasing TNM stage (p < 0.001). The same trend was observed with decreasing histopathologic grade of dierentiation and decreasing radicality of the operation.
Multivariate analysis
T-, N-and M-category, histopathologic grade, radicality of resection, sex and age were independently evaluated in a multivariate analysis. N-and M-category were both signi®cantly related to recurrence and survival (Table 3) . Male sex and older age were also identi®ed as risk factors for death.
DISCUSSIOǸ
No news': perhaps this should be the rather disappointing message from the present study. The recurrence and survival rates are unchanged compared with an earlier series at our institute comprising patients operated during the years 1983 to 1988.
1 Nor are they essentially better than those reported in earlier series from other authors. In these studies on resected adenocarcinoma of the gastric cardia or gastroesophageal junction, the 5-year survival rates after resection ranged from 10% to 29%.
11±15
Lymph node involvement and the presence of distant metastases were identi®ed in multivariate analysis as independent factors in¯uencing recurrence of disease and survival. This is a common ®nding in other series, concerning patients with cardiacarcinoma, 11 esophageal carcinoma 16, 17 or both.
18±20
In these series, 5-year survival rates of patients with negative nodes ranged from 36% to 58%, compared with 38% in the present series. Because of a growing interest in lymph node dissection and the expectation that the presence of positive nodes at the N2 location would carry a worse prognosis than cases with positive N1 nodes, the results were analyzed according to lymph node status. No dierence in recurrence or survival rates could be demonstrated between N1 or N2 positive nodes. We should realize, however, that this apparent absence of dierence might be due to the fact that no true extended lymph node dissection was carried out. As a result of this, the N-classi®cation was probably not entirely accurate.
The predominance of men and age distribution correlate with other series data. 18, 21 In our series, a better prognosis for women is observed. This corresponds to the ®ndings of a large Japanese series on esophageal and cardia carcinoma. 19 This phenomenon cannot be con®rmed by other series. 16, 22, 23 Its relevance therefore remains uncertain.
In general, we consider the presence of metastases a contraindication for resection. Nevertheless, 13 patients classi®ed in the pTNM staging as having distant metastases underwent resection. Most of these metastases were lymph nodes that were discovered when a considerable part of the resection had already been carried out, or that were found post-operatively in the resection specimen. However, in four cases, metastases were apparent at an early stage of the operation. Resection was nevertheless carried out, as it was considered the best palliation in these patients with the combination of invalidating dysphagia, relatively young age and good physical condition. What, then, is new? Do options exist to improve the future outcome after resection of a cardiacarcinoma?
Many eorts are put into optimizing preoperative tumor staging. Proper preoperative patient selection enables us to give the best treatment to each patient. Of special importance is the detection of metastases or positive lymph nodes and of a locally irresectable tumor. The presence of distant metastases is generally believed to be a contraindication for resection. Preoperative ®nding of this condition or of a locally irresectable tumor would avoid an unnecessary laparotomy. Renewed attention has been focused on the identi®cation of suspect locoregional nodes. It has been suggested that patients with a gastric carcinoma and positive nodes might bene®t from an extended lymphadenectomy. 24 If this is con®rmed by future studies, preoperative identi®cation could result in a policy of extended dissection in these selected cases.
In the past decade, several new diagnostic tools have been proven eective in enhancing the accuracy of preoperative staging, such as endoscopic ultrasonography (EUS) and laparoscopy combined with laparoscopic ultrasound (LUS). In diagnosing the T and N classi®cation, EUS is superior to conventional staging by abdominal ultrasound or computed tomography (CT) scanning. 25±27 The sensitivity and speci®city of EUS in detecting locoregional lymph node involvement range from 75% to 85% and from 70% to 88% respectively. 26, 28, 29 A novel approach is the use of a curved-array echoendoscope. 30 This facilitates EUS-guided biopsies of suspected lesions because the full length of the needle can be visualized.
For detecting distant lymph node metastases such as those at the celiac axis, CT scanning remains superior to EUS. 31 Van Overhagen et al. 32 found that these metastases and those in the supraclavicular region can be equally accurately assessed by conventional ultrasound or CT.
The value of laparoscopy, combined with laparoscopic ultrasound (LUS), lies in visualization of small intra-abdominal or peritoneal lesions and in improved detection of liver metastases, direct tumor extension and lymph node metastases in the retroperitoneum. Laparoscopy is more sensitive and accurate than ultrasonography and CT scanning with regard to evaluation of the hepatic status in patients with esophageal and cardia cancer. 33 It is also superior to conventional ultrasound in detecting intra-abdominal metastases and superior to CT and ultrasound in detecting peritoneal lesions. 27, 33 In a series on esophageal and cardia carcinoma, 38 out of 179 patients with a normal or equivocal ultrasound (US) or CT were found to have intra-abdominal tumor spread at laparoscopy that prohibited resection. 34 In a recent series, LUS provided a better N-and M-staging than CT or endoscopic ultrasonography. The authors stress the importance of adequate staging to improve selection for operation or inclusion in neoadjuvant chemotherapy trials. 35 Evidently, preoperative tumor staging has improved. This alone will not improve the outlook for our patients, but it enables us better to select patients for new therapeutic options.
One of the developments that seems of interest for patients with a cardiacarcinoma is neoadjuvant therapy. Concomitant preoperative radiotherapy and chemotherapy or pre-and post-operative chemotherapy can be considered neoadjuvant. Unfortunately, no reports have been published yet of its use in patients with a cardiacarcinoma. Promising data, however, are available on the combination of preoperative radiotherapy and chemotherapy for esophageal cancer. Leichman et al. 36 took the lead by publishing the concept in 1984. Since then, several groups have published their results using this treatment in both adenocarcinoma and squamous cell carcinoma of the esophagus. 37±39 The majority of these trials report a survival advantage of the therapy group over controls. Comparison between studies is dicult because of dierences in preoperative staging, drugs used and estimation of response. Nevertheless, especially the observation that in a subset of patients complete disappearance of the tumor occurs, which is associated with a substantial survival bene®t, is intriguing. 38±40 The feasibility of disease control and downstaging is currently being assessed for gastric cancer in the large Medical Research Council MAGIC (pre-and post-operative gastric infusional chemotherapy) Trial.
Another concept that might prove to be of bene®t for our patients is extended lymph node dissection. Until now, it is theoretically promising, but its impact in the treatment of gastroesophageal cancer still has to be established. Favorable reports from Japan are well known, yet even from this country the question is raised as to whether extended lymph node dissection is truly of therapeutic bene®t or merely represents a staging procedure. 41 Of course, more accurate staging is of great importance. Not only by enhancing the comparability of studies, but also by revealing dierences in survival or recurrence that would have remained unnoticed with less secure staging (for example, a survival dierence between N1 and N2 node-positive patients). Averbach and Jacquet 24 suggest that in stages II and IIIA gastric cancer a therapeutic advantage of extended (D2) dissection can be expected as the resection line in such dissection encompasses the N2 lymph nodes. Especially when these are free of tumor, the margin of resection is improved. On the contrary, in a limited (D1, perigastric nodes only) lymph node dissection, the resection is carried out through tissue harboring cancer in half of the patients. 42 Nevertheless, the problem of increased post-operative morbidity and mortality has not yet been solved, thereby remaining an important argument against extended lymphadenectomy.
Finally, also concerning the possible prevention of gastric and cardia carcinoma, intriguing knowledge is emerging. This is the possible relation between Helicobacter pylori infection and gastric cancer that should not remain unmentioned. McFarlane and Munro 43 comprehensively summarized the possible sequence from H. pylori infection to the development of gastric carcinoma. The majority of patients infected will remain asymptomatic with chronic active gastritis. A minority will progress to atrophic gastritis, which can subsequently lead to intestinal metaplasia, dysplasia and cancer. What determines which route the infection in the individual will follow is yet to be determined. The strain of H. pylori, the age at acquisition of the infection and genetic and environmental factors probably all play a role. The unraveling of the sequence after infection and the in¯uence of other factors thereupon may contribute to the prevention of gastric carcinoma.
In conclusion, the results of the present series compared with a previous series of our institute illustrate that the prognosis of our patients after resection of adenocarcinoma of the gastric cardia has remained unchanged over the past decade. This disappointing message emphasizes the importance of exploring new ways to improve these results. Enhancing the accuracy of preoperative tumor staging in combination with the application of new treatment regimes such as neoadjuvant therapy and extended dissection in selected patients might improve the outlook after resection of this disease. In order to de®ne the exact value of such new treatment regimes, participation in prospective randomized studies, of which several are already under way, is mandatory.
